Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026

The findings span patient follow-up, laboratory studies and a mouse comparison; ALG-170675 has advanced to Phase 1 studies.

Rhea-AI Summary

Aligos Therapeutics (ALGS) announced clinical and preclinical liver-disease findings for five presentations at The Liver Meeting 2026 in Denver.

In nine participants, inflammatory cytokine expression fell from baseline after pevifoscorvir sodium treatment, then increased during entecavir-only follow-up. Laboratory studies showed its active parent compound inhibited two hepatitis B virus DNA forms with similar potency, including one associated with viral DNA integration into the host genome.

ALG-170675 reduced hepatitis B surface antigen more than bepirovirsen in a mouse model and has advanced to Phase 1 studies in China with partner Amoytop. ALG-215007 inhibited hepatitis delta virus replication across multiple cellular systems in laboratory testing.

Positive

• Minor pointPevifoscorvir sodium reduced inflammatory cytokine expression from baseline in nine participants after treatment.
• Minor pointPevifoscorvir sodium reduced hepatitis B surface antigen to less than 3000 IU/mL following long-term on-study treatment.
• Minor pointALG-001075 inhibited both tested HBV DNA forms with similar potency; tenofovir and entecavir were less potent against the integration precursor.
• Minor pointALG-170675 reduced hepatitis B surface antigen more than bepirovirsen in a head-to-head mouse comparison.
• Minor pointALG-170675 has advanced to Phase 1 studies in China with partner Amoytop.
• Minor pointALG-215007 inhibited hepatitis delta virus replication across multiple cellular systems in laboratory testing.

Negative

• Minor pointInflammatory cytokine expression increased during entecavir-only follow-up after pevifoscorvir sodium treatment.

Key Figures

Study participants: 9 participants Monotherapy duration: 96 weeks Follow-up treatment duration: 24–48 weeks +2 more

Study participants

9 participants

HBeAg-positive participants in the pevifoscorvir sodium follow-up study

Monotherapy duration

96 weeks

Pevifoscorvir sodium monotherapy

Follow-up treatment duration

24–48 weeks

Entecavir treatment after pevifoscorvir sodium

Pevifoscorvir sodium dose

300 mg

Monotherapy in the follow-up study

HBsAg level

<3,000 IU/mL

HBeAg-positive subjects following long-term on-study treatment, as stated in a presentation title

Key Terms

antisense oligonucleotide, rnase h, pharmacokinetics, nucleos(t)ide analog, +2 more

6 terms

antisense oligonucleotide medical

"ALG-170675, a next-generation HBV antisense oligonucleotide (ASO)"

An antisense oligonucleotide is a small piece of synthetic genetic material designed to attach to specific molecules in the body’s cells, effectively blocking or modifying how genes are expressed. This technology is important because it can be used to develop targeted treatments for certain diseases, which may influence the value of biotech companies and the broader healthcare sector. Its development reflects advances in personalized medicine and gene-based therapies.

rnase h medical

"with dual RNase H and human TLR8 agonist activities"

RNase H is an enzyme that recognizes and cuts the RNA strand of an RNA–DNA hybrid, helping cells remove RNA primers during DNA replication and process RNA bound to DNA. For investors, it matters because RNase H activity is a key mechanism targeted or leveraged by certain genetic and antiviral therapies, diagnostics, and lab tools; its presence or inhibition can determine how some drugs work or how biotechnologies are developed.

pharmacokinetics medical

"efficacy in an AAV-HBV mouse model, pharmacokinetics and safety"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

nucleos(t)ide analog medical

"with the nucleos(t)ide analog entecavir (ETV)"

A nucleos(t)ide analog is a drug molecule that closely resembles a natural nucleoside or nucleotide—the building blocks of DNA and RNA—and is designed to interfere with nucleic acid synthesis. Nucleoside analogs lack a phosphate and must be converted inside cells by kinases into phosphorylated (active) forms, while nucleotide analogs already contain a phosphate or a chemically masked phosphate and therefore require fewer activation steps; once activated, these analogs can be incorporated by viral or cellular polymerases into growing DNA or RNA strands to cause chain termination or introduce errors that block further replication. Because they act during nucleic acid synthesis, their activity depends on cellular or viral enzymes for activation and on the replication machinery they target, and resistance can arise from changes in those enzymes or in the drug activation pathways.

hepatocellular carcinoma medical

"cirrhosis, and hepatocellular carcinoma (HCC) progression"

Hepatocellular carcinoma is the most common form of primary liver cancer, arising from the main functional cells of the liver. For investors it matters because its serious health impact drives demand for diagnostic tests, treatments and long-term care; progress in trials or approvals can change a drugmaker’s revenue outlook much like a successful product launch can reshape a company’s future.

hbsag medical

"deeper HBsAg knockdown than bepirovirsen in a head-to-head comparison"

HBsAg is a protein that appears on the surface of the hepatitis B virus and is detected by medical tests to show whether someone currently carries or is infectious with hepatitis B. For investors, HBsAg matters because it is a primary diagnostic and regulatory marker used in drug and vaccine trials, blood screening, and public-health programs; shifts in testing, treatment, or prevalence can affect the commercial prospects and approval pathways for related medical products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from five presentations at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO.

“The data the team will present at The Liver Meeting® underscores the strength of our pipeline,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “The pevifoscorvir sodium findings provide important new insights into the potential of a potent CAM-E compound to reduce pro-inflammatory cytokines which have been linked to disease progression in chronic HBV infection and inhibit viral HBV DNA forms associated with integration. The preclinical profile of ALG-170675, our potentially best-in-class HBV antisense oligonucleotide, which is currently progressing through a Phase 1 study in China with our partner Amoytop, further supports the promise of our next-generation approaches in chronic HBV infection. Together, these data reinforce our strategy of applying deep scientific expertise to develop potentially best-in-class therapies that can meaningfully improve patient outcomes.”

Pevifoscorvir Sodium

The data being presented will highlight findings from an investigator initiated, long term follow up study of nine HBeAg+ participants who completed 96 weeks of pevifoscorvir sodium 300 mg monotherapy, followed by 24–48 weeks of treatment with the nucleos(t)ide analog entecavir (ETV). Following pevifoscorvir sodium treatment, expression of pro-inflammatory cytokines was reduced from baseline, with increases observed during the ETV only follow up period. As persistent immune activation and inflammatory signaling are associated with disease progression in chronic HBV infection, the observed cytokine changes provide evidence that reduction in HBV biomarkers (HBV DNA, HBV RNA, antigens) by pevifoscorvir sodium may exert immunomodulatory effects. These findings are consistent with published literature linking inflammatory cytokine profiles in chronic HBV infection with immune mediated fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) progression¹.

Additionally, preclinical in vitro data demonstrate that ALG-001075, the active parent moiety of pevifoscorvir sodium, inhibited the formation of both relaxed circular DNA (rcDNA) and double-stranded linear DNA (dslDNA), the precursor form for HBV DNA integration into the host genome, with similar potency across multiple HBV cell models. In contrast, the NAs tenofovir disoproxil fumarate (TDF) and entecavir (ETV) were consistently less potent against inhibition of dslDNA than rcDNA formation. These data suggest that capsid assembly modulators may have greater potential than NAs to prevent HBV DNA integration, which can contribute to disease progression and the development of hepatocellular carcinoma.

ALG-170675

Preclinical data for ALG-170675, a next-generation HBV antisense oligonucleotide (ASO) with dual RNase H and human TLR8 agonist activities, will highlight deeper HBsAg knockdown than bepirovirsen in a head-to-head comparison in an AAV-HBV mouse model, supporting its potential best-in-class profile. ALG-170675 has advanced to Phase 1 clinical studies.

Preclinical

The preclinical posters will showcase Aligos’ and its collaborators’ continued innovation and commitment to advancing next-generation therapies in the liver and viral spaces with presentations spanning novel approaches and mechanistic insights.

Additionally, in vitro data from the hepatitis delta virus (HDV) program will show that the ASO ALG-215007 potently inhibited HDV replication across multiple cellular systems. These data suggest that the novel approach of directly targeting HDV replication could be a valuable addition to the current therapeutic arsenal.

Details on the presentations are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection

Abstract #: 4139
Title: Immune-modulatory effects of pevifoscorvir sodium in HBeAg-positive patients with chronic hepatitis B infection
Presenter: Professor Lung-Yi Loey Mak, MBBS(HK), MD(HK), MRCP(UK), PDipID (HK), FHKCP, FHKAM (Medicine), FRCP (Glasg), FRCP (Edin), FRCP, Clinical Assistant Professor at The University of Hong Kong
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B ("4001-4193"); Poster of Distinction

Abstract #: 4142
Title: Pevifoscorvir Sodium Reduces HBsAg Levels to < 3000 IU/mL in HBeAg Positive Subjects with Chronic HBV Infection Following Long-Term On-Study Treatment
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B ("4001-4193")

Abstract #: 4158
Title: Pevifoscorvir Sodium (CAM-E) is Superior to Nucleos(t)ide Analogs in Suppressing Hepatitis B Virus Double-stranded Linear DNA In Vitro
Presenter: Andreas Jekle, PhD
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B ("4001-4193")

ALG-170675: Potential best-in-class antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection

Abstract #: 4156
Title: The potentially best-in-class HBV ASO ALG-170675 demonstrates a favourable preclinical profile: efficacy in an AAV-HBV mouse model, pharmacokinetics and safety in mouse and monkey
Presenter: Jin Hong, PhD
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B ("4001-4193")

Preclinical

Abstract #: 3224
Title: Potent Inhibition of Hepatitis Delta Virus Replication by the Antisense Oligonucleotide ALG-215007
Presenter: Kellan Passow, PhD
Date/Time: November 7, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis - Other Infections ("3195-3246")

The presentations can be found on the Posters & Presentations section of the Aligos website (www.aligos.com) after the conference.

1. Chen Y, Tian Z. HBV-induced immune imbalance in the development of HCC. Front Immunol. 2019;10:2048. doi:10.3389/fimmu.2019.02048.
   
   

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ research and development activities, including whether pevifoscorvir sodium will enhance immune control of chronic HBV infection and inhibit viral HBV DNA forms associated with integration, whether ALG-170675 will ultimately be approved as a best-in-class HBV antisense oligonucleotide, whether capsid assembly modulators will prove to be better than NAs in prevention of HBV DNA integration, and whether pre-clinical results related to our programs will be predictive of clinical outcomes. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aligos report about pevifoscorvir sodium and inflammatory cytokines?

Inflammatory cytokine expression decreased from baseline after pevifoscorvir sodium treatment in nine participants, then increased during entecavir-only follow-up. Aligos said the changes suggest that reductions in hepatitis B biomarkers may have effects on immune activity.

What treatment did participants receive in Aligos' pevifoscorvir sodium follow-up study?

The nine HBeAg-positive participants completed 96 weeks of pevifoscorvir sodium 300 mg monotherapy, followed by 24–48 weeks of entecavir. The findings came from an investigator-initiated, long-term follow-up study.